1-3 of 3
William Brady
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Study of Lenalidomide and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Elizabeth A. Griffiths, MD, William Brady, Wei Tan, Carlos E Vigil, MD, James E. Thompson, MD, Laurie A Ford, BS, CCRC, Noelle M Dickey, BS, Jill Sperrazza, BS, Eunice S. Wang, MD, Meir Wetzler, MD
Journal: Blood
Blood (2014) 124 (21): 2318.
https://doi.org/10.1182/blood.V124.21.2318.2318
Published: 2014
Journal Articles

Clinical and Biologic Effects Of The Angiopoietin 1/2 Neutralizing Peptibody, Trebananib (AMG 386), In Acute Myeloid Leukemia Patients

Eunice S. Wang, MD, Gerald Fetterly, PhD, William Brady, Wei Tan, Jessica Greene, Allison Gaudy, Carlos E Vigil, MD, Jason H. Mendler, MD, PhD, Michael W. Becker, MD, Kristen O'Dwyer, MD, Jane L. Liesveld, MD, Meir Wetzler, MD
Journal: Blood
Blood (2013) 122 (21): 2701.
https://doi.org/10.1182/blood.V122.21.2701.2701
Published: 2013
Journal Articles

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naìˆve Chronic Lymphocytic Leukemia (CLL): Preliminary Results of a Phase I/II Clinical Trial.

Asher Alban Chanan-Khan, MD, Kena C. Miller, NP, Patricia Marshall, Swaminathan Padmanabhan, MD, William Brady, Zale P. Bernstein, MD, Paul Wallace, MD, Myron S. Czuczman, MD
Journal: Blood
Blood (2005) 106 (11): 2974.
https://doi.org/10.1182/blood.V106.11.2974.2974
Published: 2005